对于盆腔炎症疾病的可用药物标:孟德尔的随机化和实验验证
Chunxiao Dang1, Qing Wu2, Jing Pan1
1First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, People's Republic of China.
Journal of inflammation research
|September 25, 2025
概括
盆腔炎症疾病 (PID) 的治疗方法有限. 这项研究使用了门德尔的随机化来识别可药物基因 (ALB,IL6,CD4) 并发现苏尼提尼布和埃弗罗利莫斯对PID治疗具有前途.
科学领域:
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
- 妇科 妇科 妇科 妇科
背景情况:
- 盆腔炎症疾病 (PID) 是一种普遍的妇科疾病,对健康有重大影响.
- 目前对PID的治疗选择有限,需要新的治疗策略.
研究的目的:
- 用一种可用药物治疗的全基因组门德尔随机化 (MR) 方法来确定PID的潜在治疗标.
- 探索用于PID治疗的药物重用机会.
主要方法:
- 系统性可治疗的全基因组MR分析,整合cis-eQTL和PID GWAS数据.
- 使用局部化,药物预测和分子对接来识别候选药物和目标.
- 用PID的小鼠模型进行验证,以评估基因表达变化.
主要成果:
- 通过MR,局部化和蛋白质相互作用分析确定了六个关键基因.
- 苏尼提尼布和埃弗罗利斯被确定为潜在的药物,针对白蛋白 (ALB),介质素6 (IL6) 和分化集群4 (CD4).
- 在PID大鼠模型中,ALB和IL6的表达减少,而CD4的表达增加.
结论:
- 遗传证据支持ALB,IL6和CD4作为PID可行的可用药物标.
- 苏尼蒂尼布和埃弗罗利斯在临床前模型中显示出有效性,这表明了重定向的潜力.
- 在PID大鼠模型中,ALB,IL6和CD4的差异表达在体内得到证实.
更多相关视频
相关概念视频
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...


